JP7481261B2 - 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用 - Google Patents
腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用 Download PDFInfo
- Publication number
- JP7481261B2 JP7481261B2 JP2020554857A JP2020554857A JP7481261B2 JP 7481261 B2 JP7481261 B2 JP 7481261B2 JP 2020554857 A JP2020554857 A JP 2020554857A JP 2020554857 A JP2020554857 A JP 2020554857A JP 7481261 B2 JP7481261 B2 JP 7481261B2
- Authority
- JP
- Japan
- Prior art keywords
- mer
- tendon
- pedf
- derived
- pdsp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000102 pigment epithelium-derived factor Proteins 0.000 title claims description 32
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 title claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 28
- 210000002435 tendon Anatomy 0.000 title description 56
- 230000035876 healing Effects 0.000 title description 12
- 102000004196 processed proteins & peptides Human genes 0.000 title description 9
- 208000021945 Tendon injury Diseases 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 102000007079 Peptide Fragments Human genes 0.000 claims description 5
- 108010033276 Peptide Fragments Proteins 0.000 claims description 5
- 101001073422 Homo sapiens Pigment epithelium-derived factor Proteins 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 19
- 235000010443 alginic acid Nutrition 0.000 description 19
- 229920000615 alginic acid Polymers 0.000 description 19
- 229940072056 alginate Drugs 0.000 description 18
- 230000035755 proliferation Effects 0.000 description 18
- 238000006467 substitution reaction Methods 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 210000000130 stem cell Anatomy 0.000 description 11
- HGCFMGDVMNCLNU-UHFFFAOYSA-N 3-thiophen-2-ylsulfonylpyrazine-2-carbonitrile Chemical compound N=1C=CN=C(C#N)C=1S(=O)(=O)C1=CC=CS1 HGCFMGDVMNCLNU-UHFFFAOYSA-N 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 235000004279 alanine Nutrition 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 210000001361 achilles tendon Anatomy 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000011552 rat model Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000006311 Cyclin D1 Human genes 0.000 description 5
- 108010058546 Cyclin D1 Proteins 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 102220037837 rs76224028 Human genes 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 102100031168 CCN family member 2 Human genes 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 4
- 102100021185 Guanine nucleotide-binding protein-like 3 Human genes 0.000 description 4
- 101710147092 Guanine nucleotide-binding protein-like 3 Proteins 0.000 description 4
- 102220610750 Thialysine N-epsilon-acetyltransferase_Q98A_mutation Human genes 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002297 mitogenic effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102220280441 rs776730435 Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000002737 cell proliferation kit Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000001074 muscle attachment cell Anatomy 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 206010043248 Tendon rupture Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000426 patellar ligament Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- VHRUMKCAEVRUBK-GODQJPCRSA-N 15-deoxy-Delta(12,14)-prostaglandin J2 Chemical compound CCCCC\C=C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-GODQJPCRSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102220475889 Hydroxycarboxylic acid receptor 1_R99A_mutation Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102220467332 Protein BEX4_L94A_mutation Human genes 0.000 description 1
- 101150106167 SOX9 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- -1 alginic acid sodium salt Chemical class 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000000459 calcaneus Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 238000001317 epifluorescence microscopy Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012913 medium supplement Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000732 tissue residue Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024018183A JP2024054273A (ja) | 2018-04-08 | 2024-02-08 | 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862654466P | 2018-04-08 | 2018-04-08 | |
| US62/654,466 | 2018-04-08 | ||
| PCT/US2019/026307 WO2019199661A1 (en) | 2018-04-08 | 2019-04-08 | Application of pedf-derived short peptides in tendon healing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024018183A Division JP2024054273A (ja) | 2018-04-08 | 2024-02-08 | 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521113A JP2021521113A (ja) | 2021-08-26 |
| JP2021521113A5 JP2021521113A5 (enExample) | 2022-04-13 |
| JP7481261B2 true JP7481261B2 (ja) | 2024-05-10 |
Family
ID=68163751
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554857A Active JP7481261B2 (ja) | 2018-04-08 | 2019-04-08 | 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用 |
| JP2024018183A Pending JP2024054273A (ja) | 2018-04-08 | 2024-02-08 | 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024018183A Pending JP2024054273A (ja) | 2018-04-08 | 2024-02-08 | 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210244791A1 (enExample) |
| EP (1) | EP3761959A4 (enExample) |
| JP (2) | JP7481261B2 (enExample) |
| KR (1) | KR20200142521A (enExample) |
| CN (1) | CN113038929A (enExample) |
| AU (2) | AU2019251091A1 (enExample) |
| EA (1) | EA202092368A1 (enExample) |
| IL (1) | IL277689B2 (enExample) |
| TW (1) | TWI902659B (enExample) |
| WO (1) | WO2019199661A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024054273A (ja) * | 2018-04-08 | 2024-04-16 | ブリム バイオテクノロジー インク | 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015525786A (ja) | 2012-08-09 | 2015-09-07 | マクカイ メモリアル ホスピタル | 筋肉若しくは腱再生又は動脈形成を促進するためのｐｅｄｆ由来のポリペプチドの使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035655T2 (en) * | 2005-08-05 | 2018-05-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and their use |
| WO2007095350A2 (en) * | 2006-02-15 | 2007-08-23 | Yale University | Compositions and methods for use of pigment epithelial derived factor (pedf) peptide fragments |
| ES2329636B2 (es) * | 2006-02-17 | 2010-07-26 | Universitat De Valencia, Estudi General (Participa Con El 70%) | Uso del factor pedf para inducir la auto-renovacion de celulas madre. |
| EP2508196B1 (en) * | 2011-03-23 | 2018-09-26 | Mackay Memorial Hospital | Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing |
| TWI491616B (zh) * | 2012-08-09 | 2015-07-11 | Mackay Memorial Hospital | 色素上皮衍生因子衍生之多胜肽於促進肌肉或肌腱再生或動脈血管生成之用途 |
| EA037698B1 (ru) * | 2016-10-07 | 2021-05-12 | Брим Байотекнолоджи, Инк. | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение |
| IL277689B2 (en) * | 2018-04-08 | 2024-12-01 | Brim Biotechnology Inc | Application of pedf-derived short peptides in tendon healing |
-
2019
- 2019-04-08 IL IL277689A patent/IL277689B2/en unknown
- 2019-04-08 JP JP2020554857A patent/JP7481261B2/ja active Active
- 2019-04-08 KR KR1020207031085A patent/KR20200142521A/ko not_active Ceased
- 2019-04-08 CN CN201980038546.7A patent/CN113038929A/zh active Pending
- 2019-04-08 US US17/053,047 patent/US20210244791A1/en not_active Abandoned
- 2019-04-08 EP EP19785477.1A patent/EP3761959A4/en active Pending
- 2019-04-08 AU AU2019251091A patent/AU2019251091A1/en not_active Abandoned
- 2019-04-08 WO PCT/US2019/026307 patent/WO2019199661A1/en not_active Ceased
- 2019-04-08 EA EA202092368A patent/EA202092368A1/ru unknown
- 2019-04-08 TW TW108112195A patent/TWI902659B/zh active
-
2024
- 2024-02-08 JP JP2024018183A patent/JP2024054273A/ja active Pending
-
2025
- 2025-03-04 AU AU2025201569A patent/AU2025201569A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015525786A (ja) | 2012-08-09 | 2015-09-07 | マクカイ メモリアル ホスピタル | 筋肉若しくは腱再生又は動脈形成を促進するためのｐｅｄｆ由来のポリペプチドの使用 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024054273A (ja) * | 2018-04-08 | 2024-04-16 | ブリム バイオテクノロジー インク | 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113038929A (zh) | 2021-06-25 |
| WO2019199661A1 (en) | 2019-10-17 |
| TWI902659B (zh) | 2025-11-01 |
| EA202092368A1 (ru) | 2021-01-18 |
| IL277689A (en) | 2020-11-30 |
| EP3761959A1 (en) | 2021-01-13 |
| JP2021521113A (ja) | 2021-08-26 |
| AU2025201569A1 (en) | 2025-05-22 |
| IL277689B2 (en) | 2024-12-01 |
| EP3761959A4 (en) | 2022-03-02 |
| KR20200142521A (ko) | 2020-12-22 |
| US20210244791A1 (en) | 2021-08-12 |
| IL277689B1 (en) | 2024-08-01 |
| JP2024054273A (ja) | 2024-04-16 |
| AU2019251091A1 (en) | 2020-11-26 |
| TW202010513A (zh) | 2020-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9884012B2 (en) | Use of PEDF-derived polypeptides for promoting muscle or tendon regeneration or arteriogenesis | |
| Nazareth et al. | Differing phagocytic capacities of accessory and main olfactory ensheathing cells and the implication for olfactory glia transplantation therapies | |
| KR101757523B1 (ko) | 구획 증후군의 치료에 사용하기 위한 항분비 단백질 | |
| JP2024054274A (ja) | 変形性関節症の治療におけるｐｅｄｆ由来短鎖ペプチドの使用 | |
| Agnić et al. | Effects of isoflurane postconditioning on chronic phase of ischemia–reperfusion heart injury in rats | |
| Ashraf et al. | RHEB gene therapy maintains the chondrogenic characteristics and protects cartilage tissue from degenerative damage during experimental murine osteoarthritis | |
| JP2024054273A (ja) | 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用 | |
| US20210379104A1 (en) | Pharmaceutical composition comprising isolated mitochondria for preventing or treating tendinopathy | |
| KR101736280B1 (ko) | 관절염 예방 또는 치료용 약학적 조성물 | |
| Kukharchuk et al. | Fetal progenitor cells for treatment of chronic limb ischemia | |
| Qiu et al. | Bone marrow mesenchymal stem cells overexpressing FGF-2 loaded onto a decellularized extracellular matrix hydrogel for the treatment of osteoarthritis | |
| US8999928B2 (en) | Methods for treating diseases using a bone morphogenetic protein | |
| TWI491616B (zh) | 色素上皮衍生因子衍生之多胜肽於促進肌肉或肌腱再生或動脈血管生成之用途 | |
| JP2017165745A (ja) | 筋肉若しくは腱再生又は動脈形成を促進するためのｐｅｄｆ由来のポリペプチドの使用 | |
| JP2024046128A (ja) | 骨形成促進剤 | |
| WO2024005133A1 (ja) | 半月板の治療薬 | |
| Ho et al. | Articles in PresS. Am J Physiol Cell Physiol (June 3, 2015). doi: 10.1152/ajpcell. 00344.2014 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220405 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220405 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230421 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230623 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230724 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230725 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231010 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240301 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240327 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240423 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240425 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7481261 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |